Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell reported an award of phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors. He received 420.97 phantom stock units tied on a 1-for-1 basis to common stock, bringing his total phantom stock holdings to 18,245.033 units.
The phantom stock units are cash-settled in a lump sum within sixty days after he ceases serving as a director. His total includes 48.381 phantom stock units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. is asking shareholders to vote at its May 22, 2026 virtual annual meeting on four key items: electing 10 directors, ratifying PricewaterhouseCoopers as auditor for 2026, approving executive pay on an advisory basis, and a shareholder proposal for an independent board chairman.
The Board highlights a largely independent, skills-diverse slate, strong governance features such as majority voting, proxy access, board evaluations and stock ownership guidelines, and an enhanced Lead Independent Director role when the CEO also serves as Chairman. The company reports 2025 net sales growth of 7.2%, aided by acquisitions and new products, and explains that over 90% of the CEO’s 2025 target pay was performance-based, with annual bonuses and performance stock units tied to constant currency revenue growth, adjusted earnings, free cash flow and relative total shareholder return.
Zimmer Biomet Holdings Inc ownership update: The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A disclosing that it beneficially owns 0 shares of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an open-market sale of company stock. She sold 2,650 shares of common stock at an average price of $94.66 per share. After this transaction, she directly holds 10,224 shares of Zimmer Biomet common stock.
ZBH submitted a Form 144 listing proposed transactions in Common Stock tied to restricted stock vesting events. The filing lists vesting entries dated 03/06/2025, 02/20/2026, 02/25/2026, and 03/06/2026 with quantities including 1, 1,162, 1,423, and 64 shares respectively. The excerpt names Fidelity Brokerage Services LLC as a broker/agent and references the NYSE.
Zimmer Biomet Holdings Exec VP & CFO Suketu Upadhyay exercised restricted stock units into 14,776 shares of common stock on March 6, 2026. To cover tax obligations on this RSU vesting, 6,576 shares were withheld by the company at $92.54 per share. After these compensation-related transactions, Upadhyay directly holds 69,485 shares of Zimmer Biomet common stock.
Zimmer Biomet Holdings, Inc. Group President EMEA Wilfred Van Zuilen exercised restricted stock units on March 6, 2026, converting 7,004 RSUs into common shares. The company withheld 1,822 shares at $92.54 per share to cover tax obligations, leaving a net 5,182 shares. Following these compensation-related transactions, he directly holds 30,991 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity. On March 6, 2026, restricted stock units converted into 5,634 shares of common stock, with each RSU representing one share.
To cover tax withholding obligations on the RSU vesting, the company withheld 2,178 shares at a reference price of $92.54 per share, as disclosed. After these transactions, Winkler directly owns 12,874 shares of Zimmer Biomet common stock. The filing shows no open‑market purchases or sales, only RSU vesting and tax withholding.
Zimmer Biomet Holdings executive Yi Sang, Group President, Asia Pacific, reported the exercise and conversion of restricted stock units into common stock. On March 6, 2026, he exercised a total of 9,414 restricted stock units, receiving an equal number of common shares.
Following these transactions, Yi Sang directly owned 32,251 shares of common stock. The restricted stock units converted at no cash exercise price, reflecting the vesting of equity-based compensation rather than open-market purchases or sales.